Trial Profile
Dolutegravir in Pregnant HIV Mothers and Their Neonates
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DolPHIN-2
- 06 Mar 2024 Results assessing efficacy of dolutegravir (DTG) versus efavirenz (EFV) in pregnant & postpartum women in this trial were presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 06 Mar 2024 Results of secondary analysis of DolPHIN-2 trial, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024